Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Venetoclax + SC/IV Azacitidine Safety & Efficacy in ND AML Adults in India
Details : Venetoclax is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2025
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mitomycin C is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 17, 2025
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Venetoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 03, 2021
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urate Oxidase
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rasburicase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : Urate Oxidase
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibrutinib
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Details : Ibrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2017
Lead Product(s) : Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 30, 2015
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 12, 2015
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Panitumumab
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Details : Panitumumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 26, 2014
Lead Product(s) : Panitumumab
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 28, 2014
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 25, 2012
Lead Product(s) : Cabazitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
